Oxford BioMedica acquires ocular drug delivery IP from Clayton Foundation
This article was originally published in Scrip
Executive Summary
Oxford BioMedica has acquired the rights to intellectual property that supports its ocular products RetinoStat and Encorstat from the Research Development Foundation, the technology transfer arm of the Clayton Foundation for Research.